ASND

COPENHAGEN, Denmark, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will share the latest data from its Endocrinology Rare Disease programs during ESPE 2026, the annual congress of the European Society for Paediatric Endocrinology (ESPE) being held September 8-10, 2026, in Marseille, France. Updates will include a podium presentation of the first sentinel cohort data from the pivotal reACHin Trial of TransCon CNP (navepegritide) in infants with achondroplasia aged 0 to

COPENHAGEN, Denmark, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has entered into a binding term sheet for a global settlement and license agreement with BioMarin Pharmaceutical Inc. (“BioMarin”) related to the sale of YUVIWEL® and navepegritide-related products. The binding term sheet provides the terms and conditions upon which the companies agree to resolve all litigation and disputes between the companies.

COPENHAGEN, Denmark, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its participation at ISDS 2026, the annual meeting of the International Skeletal Dysplasia Society being held in Toronto, Canada, from August 26-29, 2026, will include an oral presentation of Week 104 data from its pivotal ApproaCH Trial of once-weekly TransCon CNP (navepegritide) in children with achondroplasia. The presentation will be given by Carlos Bacino, M.D., FACMG, Professor of Molecular and Human Genetics, Baylor College of Medicine and Texas Children's Hospital.

First patients dosed in OVERTURE, a Phase 1b/2a study evaluating EYC-0305, a potential long-acting anti-VEGF therapy designed for six-month or longer dosing intervals via standard intravitreal injection

Ascendis Pharma A/S (ASND) Q2 2026 Earnings Call Transcript

Ascendis Pharma A/S NASDAQ: ASND reported second-quarter 2026 total revenue of EUR 339 million, including EUR 315 million in product revenue, as demand for its three commercial TransCon-based therapies continued to increase.

– Q2 2026 product revenue of €315 million (+105% Y/Y), comprising €252 million for YORVIPATH ® , €55 million for SKYTROFA ® , and €8 million for YUVIWEL ®

COPENHAGEN, Denmark, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided updates across its achondroplasia programs.

Crinetics Pharmaceuticals (NASDAQ:CRNX | CRNX Price Prediction) shares have climbed 99% just this week, from $42.03 at Monday's close, to $83.54 earlier today.

COPENHAGEN, Denmark, June 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new radiographic data from Week 104 from the completed pivotal ApproaCH Trial of once-weekly TransCon CNP (navepegritide) in children with achondroplasia. In the trial, TransCon CNP-treated children demonstrated continued improvements in lower extremity alignment through up to two years of treatment, including improvements in tibial-femoral angle (TFA). As previously reported, improvements in annualized growth velocity were maintained and ACH-specific height Z-score increased with TransCon CNP treatment through Week 104. The data were presented by Leanne M. Ward, M.D., FRCPC, Professor of Pediatrics at the University of Ottawa and Children's Hospital of Eastern Ontario, during the 12th International Conference on Children's Bone Health (ICCBH 2026) held in Montreal, Canada.